Treatment of Spinal Cord Compression

Immediate Management

High-dose dexamethasone before radiotherapy significantly improves ambulation rates (81% vs 63% at 3 months) compared to no corticosteroids, according to the American Society of Clinical Oncology 1
MRI has sensitivity 0.44-0.93 and specificity 0.90-0.98 for diagnosing malignant spinal cord compression, as recommended by the American College of Radiology 1
Myelography is an alternative with sensitivity 0.71-0.97 and specificity 0.88-1.00, as suggested by the American College of Radiology 1

Definitive Treatment Selection

The American College of Radiology recommends surgery followed by radiotherapy for patients with single level of compression, neurologic deficits present for <48 hours, and predicted survival ≥3 months 2
Bony retropulsion or bone fragments causing cord compression are absolute indications for surgery, according to the European Society for Medical Oncology 3
Surgery improves ambulatory status: Patients receiving surgery plus radiotherapy maintain ambulation longer than radiotherapy alone (P=0.006), as reported by the American Society of Clinical Oncology 4

Radiotherapy

The American Society of Clinical Oncology recommends standard radiotherapy regimen: 30 Gy in 10 fractions 5
Alternative regimens include 37.5 Gy in 15 fractions, 40 Gy in 20 fractions, or 28 Gy in 7 fractions—no regimen demonstrates superiority, according to the American Society of Clinical Oncology 5
Pain relief may be delayed up to 2 weeks following treatment, as noted by the American College of Radiology 2

Prognostic Factors

Pretreatment ambulatory status is a critical determinant of outcome, with ambulatory patients having 96-100% chance of remaining ambulatory after treatment, as reported by the American Society of Clinical Oncology 5
Patients with slower development of motor deficits (>14 days) have better functional outcomes than rapid progression (<14 days), according to the American Society of Clinical Oncology 6

Treatment Delays and Recognition

The American Society of Clinical Oncology recommends managing patients with suspected spinal cord compression to minimize treatment delay, as 70% of patients experience loss of neurologic function between symptom onset and treatment initiation 1
Two-thirds of delays are attributed to patients not recognizing symptoms as urgent, as noted by the American Society of Clinical Oncology 6

Adjunctive Management

The European Society for Medical Oncology recommends bone-directed therapy, such as zoledronic acid 4 mg IV over 15 minutes monthly or pamidronate 90 mg IV over 2 hours monthly, for bone disease 3
Vertebroplasty or kyphoplasty may be used for severe back pain from vertebral compression fractures, as suggested by the European Society for Medical Oncology 3

Treatment for Spinal Cord Compression

Initial Management

The American College of Radiology recommends high-dose dexamethasone therapy immediately upon clinical suspicion of spinal cord compression, even before radiographic confirmation, with a standard regimen of 96 mg IV daily, tapered over 14 days, although this carries significant toxicity risk 7, 8
MRI of the entire spine should be performed urgently to confirm the diagnosis 7, 9

Surgical Management

The American College of Radiology recommends surgery as the standard of care for spinal cord compression with frank spinal instability, neurologic deficits, or bony retropulsion causing cord compression 10, 11
Surgical decompression followed by radiation therapy is superior to radiation therapy alone for patients with age <65 years, single level compression, neurologic deficits present for <48 hours, or predicted survival of at least 3 months 11
In multiple myeloma patients, if cord compression is due to bone fragments, surgery should be performed 8, 12

Radiation Therapy

Radiation therapy is a mainstay treatment for spinal cord compression, with a standard regimen of 30 Gy in 10 fractions 9
Patients who undergo surgery should receive radiation therapy post-operatively once healing has occurred 8, 12

Prognostic Factors

Pretreatment neurologic status is the strongest prognostic factor for overall survival and ability to ambulate after treatment 13
Recovery of neurologic function is highly dependent on pretreatment status, with only 30% of non-ambulatory patients regaining ability to walk and only 2-6% of paraplegic patients regaining ambulatory function 12, 8

Important Caveats

Delay in diagnosis and treatment can lead to irreversible neurologic deficits 13
The combination of surgery plus radiation therapy has shown better outcomes than radiation therapy alone in selected patients 7, 9
Stereotactic body radiation therapy provides higher radiation doses but carries a higher risk of vertebral compression fracture 11, 10

Management of Metastatic Spinal Cord Compression

Corticosteroid Therapy

Initiate dexamethasone immediately on clinical suspicion of spinal cord compression, before imaging confirmation, using a high‑dose regimen of 96 mg IV bolus followed by 96 mg orally daily for 3 days and then tapering over 10 days (NCCN guidelines) 14.
An alternative moderate‑dose regimen of 16 mg dexamethasone daily (divided q6 h) provides comparable efficacy with a better safety profile for patients with a stable spine and no rapidly progressive neurologic deficit (NCCN guidelines) [15][16].
High‑dose dexamethasone improves ambulation at 3 months (81 % vs 63 % with no steroids) (Level I evidence) 14.
High‑dose dexamethasone is associated with significant toxicity in 11–29 % of patients (GI perforation, bleeding, one fatal ulcer) (Level I evidence) 14.

Radiation Therapy Regimens

Standard preferred regimen: 30 Gy in 10 fractions (NCCN guidelines) [15][14].
Equivalent alternative fractionations include 8 Gy single fraction, 20 Gy in 5 fractions, or 37.5 Gy in 15 fractions (Annals of Oncology guideline) 17.
For patients with longer expected survival, more protracted schedules such as 10 × 3 Gy or 5 × 4 Gy may be considered (Annals of Oncology guideline) 17.
Hypofractionated regimens (8 Gy single dose or 20 Gy/5 fractions) are recommended for limited life expectancy (<3–6 months), poor performance status, or when convenience is a priority (Annals of Oncology guideline) 17.
Protracted regimens (30–40 Gy in 10–20 fractions) are advised for good performance status with life expectancy >6 months, radiosensitive tumors (breast, prostate, lymphoma, myeloma) (NCCN guidelines) [15][16], and for younger patients (<65 years) with controlled primary disease (Chest guideline) 14.

Timing and Prognostic Factors

Begin definitive treatment (steroids + radiotherapy) within 24 hours of diagnosis to prevent irreversible neurologic injury (Level II evidence) 18.
Pretreatment ambulatory status is the strongest predictor of outcome: 96–100 % of patients who are ambulatory before therapy remain ambulatory, whereas only ~30 % of non‑ambulatory patients regain walking ability (Level II evidence) 18.

Surgical Indications

Absolute indications for surgical decompression followed by radiotherapy include spinal instability (kyphosis, subluxation, retropulsed bone fragments) and bony compression causing cord compression (NCCN guidelines) [15][16].
Surgery is not indicated for hematologic malignancies (lymphoma, myeloma, leukemia) because these tumors are highly radiosensitive (NCCN guidelines) [15][16]; for patients who have been paraplegic >24 hours (NCCN guidelines) [15][16]; or when life expectancy is <3 months (NCCN guidelines) 15.

Bone‑Directed Adjunctive Therapy

Add a bone‑modifying agent—either zoledronic acid 4 mg IV monthly or denosumab—to reduce pathological fractures and subsequent spinal cord compression events (Annals of Oncology guideline) [19][20]17.

Clinical Pitfalls

Do not delay steroid administration while awaiting MRI; start dexamethasone on clinical suspicion (NCCN guideline) 14.
Avoid prolonged high‑dose steroid courses; taper quickly after radiotherapy initiation to limit toxicity (Chest guideline) 14.
Recognize that only 32–35 % of patients with back pain and bone metastases actually have cord compression on MRI (Level II evidence) 18.

Evidence‑Based Diagnostic Imaging and Radiotherapy for Aggressive Vertebral Hemangioma

Diagnostic Imaging

Magnetic resonance imaging of the entire spine is the preferred diagnostic tool, demonstrating a sensitivity ranging from 44 % to 93 % and a specificity from 90 % to 98 % for identifying aggressive vertebral hemangiomas that cause spinal cord compression 21.

Radiotherapy

Low‑dose external‑beam radiotherapy (total dose 10–30 Gy) effectively reduces the risk of tumor recurrence after surgical treatment of aggressive vertebral hemangioma 22.
Patients may experience a delay of up to two weeks before noticeable pain relief is achieved following low‑dose radiotherapy 22.

Urgent Surgical Decompression in Metastatic Epidural Spinal Cord Compression

Indications for Surgery

Surgery is the preferred treatment for patients with metastatic epidural spinal cord compression (MESCC) who develop neurological deterioration while receiving radiotherapy and corticosteroids, according to the Dutch national guideline (2018) 23.
Progressive neurological deficits constitute a clear indication for urgent surgical decompression in MESCC, as stated by the Dutch national guideline (2018) 23.
When neurological symptoms worsen despite optimal steroid therapy, the guideline recommends proceeding to surgical intervention (Cancer Treatment Reviews 2018) 23.

Contraindications to Conservative Management

Conservative (non‑surgical) management is contraindicated in MESCC when there is ongoing deterioration of neurological function, per the guideline (2018) 23.
Escalating medical therapy (e.g., increasing steroid dose) is discouraged once neurological function is actively declining; urgent surgery should be pursued, according to the guideline (2018) 23.

Role of Chemotherapy

Chemotherapy has no role in the acute management of spinal cord compression unless the underlying tumor is highly chemosensitive (e.g., lymphoma, multiple myeloma), as specified by the guideline (2018) 23.

Timing of Intervention

Treatment for MESCC must be initiated within 24 hours of diagnosis to prevent irreversible neurologic injury, mandated by the Dutch national guideline (2018) 23.